Oncimmune Holdings PLC PDMR Dealing (5784H)

TIDMONC

RNS Number : 5784H

Oncimmune Holdings PLC

25 March 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Meinhard Schmidt, PDMR and Non-Executive Chairman, has purchased 18,000 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") for 49 pence per share on 24 March 2020.

Following this transaction, Meinhard has a total interest in the Company of 18,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's issued Ordinary Share capital.

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                Meinhard Schmidt 
      ----------------------------------  -------------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------------- 
 a)    Position/status                     Non-Executive Chairman 
      ----------------------------------  -------------------------------------- 
 b)    Initial                             Initial notification 
        notification 
        /Amendment 
      ----------------------------------  -------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------- 
 a)    Name                                Oncimmune Holdings plc 
      ----------------------------------  -------------------------------------- 
 b)    LEI                                 213800HCYIWT6YPI1I02 
      ----------------------------------  -------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      -------------------------------------------------------------------------- 
 a)    Description                         Ordinary Shares of GBP0.01 each 
        of the 
        financial 
        instrument, 
        type of 
        instrument 
 
       Identification                      ISIN: GB00BYQ94H38 
        code 
 
 b)    Nature                              Purchase of shares 
        of the 
        transaction 
      ----------------------------------  -------------------------------------- 
 c)    Price(s) 
        and volume(s) 
                                           -------------------  -------------- 
                                            Price                Volume 
                                           -------------------  -------------- 
    GBP0.49                                                      18,000 
   -----------------------------------------------------------  -------------- 
 
 d)    Aggregated 
        information 
 
  - Aggregated                        Same as above 
   volume 
 
  - Price 
 
 e)    Date of                             24 March 2020 
        the transaction 
      ----------------------------------  -------------------------------------- 
 f)    Place of                            London stock exchange, AIM 
        the transaction 
      ----------------------------------  -------------------------------------- 
 

For further information:

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

[e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHKKPBQBBKDDNB

(END) Dow Jones Newswires

March 25, 2020 08:42 ET (12:42 GMT)